READ THE LATEST CAPITAL IDEAS DIGEST
![](https://capitalideasmedia.com/wp-content/uploads/2019/02/Screen-Shot-2019-02-12-at-9.19.19-AM.png)
10 Dividend All-Stars for 2019
Also inside: New analyst coverage of two cannabis companies. One’s a leader in extraction with 100%+ upside, the other a best-in-class multi-state operator. Plus: Three stocks that could keep going higher.
![](https://capitalideasmedia.com/wp-content/uploads/2019/02/shutterstock_1029299632.jpg)
Tech Company Returning to Growth with 80% Upside
Also inside: Top U.S. hemp-based CBD seller an established leader at the right time. Plus: Gold company could be acquisition target with projected return of 73%.
![](https://capitalideasmedia.com/wp-content/uploads/2019/01/shutterstock_759361189.jpg)
Fast-Growth, Cash-Rich & Low Risk with 25% Upside
Also inside: New analyst coverage of cobalt and gold plays with projected returns of nearly 80% and 130%. Plus: This software stock has broken out after building a base for four years.
![](https://capitalideasmedia.com/wp-content/uploads/2019/01/shutterstock_1034922175.jpg)
KeyStone Research on Global Cannabis Candidates
Also inside: New coverage of a U.S. marijuana player that has 109% upside. Plus: Four stock ideas for the new four-year market cycle.
![](https://capitalideasmedia.com/wp-content/uploads/2019/01/shutterstock_224311546.jpg)
Five High-Growth, Catalyst-Rich Small Cap Top Picks
Also inside: New coverage of a multi-faceted U.S. cannabis company with 50% upside. Plus: Three Canadian top picks offering growth and value.
![](https://capitalideasmedia.com/wp-content/uploads/2019/01/shutterstock_1172619169.jpg)
Best Ideas of 2019 from Our All-Star Contributors
Inside: 12 hand-selected stock picks from the likes of Fabrice Taylor, Ryan Irvine, Peter Hodson, Roger Dent and more. Plus: Dwight Galusha’s favorite chart set up for this year.
![](https://capitalideasmedia.com/wp-content/uploads/2018/12/shutterstock_356148236.jpg)
E-Commerce Operator Outperforming Amazon
Also inside: New coverage of a “high conviction” Canadian health care technology company. Plus: Our best and worst ideas of 2018.
![](https://capitalideasmedia.com/wp-content/uploads/2018/12/shutterstock_108748433.jpg)
Biotech Could Surge 245% on Manmade CBD Drug
Also inside: Relax, take the long view, and get off your phone. Plus: This gas purification company has a record backlog and a projected return of nearly 130%.